Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Engulfment and cell motility protein 1 potentiates diabetic cardiomyopathy via Rac-dependent and Rac-independent ROS production
Masao Kakoki, Edward M. Bahnson, John R. Hagaman, Robin M. Siletzky, Ruriko Grant, Yukako Kayashima, Feng Li, Esther Y. Lee, Michelle T. Sun, Joan M. Taylor, Jessica C. Rice, Michael F. Almeida, Ben A. Bahr, J. Charles Jennette, Oliver Smithies, Nobuyo Maeda-Smithies
Masao Kakoki, Edward M. Bahnson, John R. Hagaman, Robin M. Siletzky, Ruriko Grant, Yukako Kayashima, Feng Li, Esther Y. Lee, Michelle T. Sun, Joan M. Taylor, Jessica C. Rice, Michael F. Almeida, Ben A. Bahr, J. Charles Jennette, Oliver Smithies, Nobuyo Maeda-Smithies
View: Text | PDF
Research Article Cardiology

Engulfment and cell motility protein 1 potentiates diabetic cardiomyopathy via Rac-dependent and Rac-independent ROS production

  • Text
  • PDF
Abstract

Engulfment and cell motility protein 1 (ELMO1) is part of a guanine nucleotide exchange factor for Ras-related C3 botulinum toxin substrate (Rac), and ELMO1 polymorphisms were identified to be associated with diabetic nephropathy in genome-wide association studies. We generated a set of Akita Ins2C96Y diabetic mice having 5 graded cardiac mRNA levels of ELMO1 from 30% to 200% of normal and found that severe dilated cardiomyopathy develops in ELMO1-hypermorphic mice independent of renal function at age 16 weeks, whereas ELMO1-hypomorphic mice were completely protected. As ELMO1 expression increased, reactive oxygen species indicators, dissociation of the intercalated disc, mitochondrial fragmentation/dysfunction, cleaved caspase-3 levels, and actin polymerization increased in hearts from Akita mice. Cardiomyocyte-specific overexpression in otherwise ELMO1-hypomorphic Akita mice was sufficient to promote cardiomyopathy. Cardiac Rac1 activity was positively correlated with the ELMO1 levels, and oral administration of a pan-Rac inhibitor, EHT1864, partially mitigated cardiomyopathy of the ELMO1 hypermorphs. Disrupting Nox4, a Rac-independent NADPH oxidase, also partially mitigated it. In contrast, a pan-NADPH oxidase inhibitor, VAS3947, markedly prevented cardiomyopathy. Our data demonstrate that in diabetes mellitus ELMO1 is the “rate-limiting” factor of reactive oxygen species production via both Rac-dependent and Rac-independent NADPH oxidases, which in turn trigger cellular signaling cascades toward cardiomyopathy.

Authors

Masao Kakoki, Edward M. Bahnson, John R. Hagaman, Robin M. Siletzky, Ruriko Grant, Yukako Kayashima, Feng Li, Esther Y. Lee, Michelle T. Sun, Joan M. Taylor, Jessica C. Rice, Michael F. Almeida, Ben A. Bahr, J. Charles Jennette, Oliver Smithies, Nobuyo Maeda-Smithies

×

Figure 2

Histology and cardiac functions with echocardiography and pressure-volume loop study.

Options: View larger image (or click on image) Download as PowerPoint
Histology and cardiac functions with echocardiography and pressure-volum...
“LLA+ Myh6-Cre” indicates LLA+ mice with the cardiomyocyte-specific Cre transgene; dotted lines indicate nondiabetic WT levels. The number of animals studied is shown in each figure. Data are expressed as mean ± SEM. Comparisons were done with 1-way ANOVA including the additional data set. *P < 0.05 vs. WTA+ mice by Tukey-Kramer Honestly Significant Differences test. (A) AZAN trichrome staining of the heart. Scale bar: 1 mm. (B) Representative M-mode echocardiograms. (C) Ejection fraction of the left ventricles (LVEF). (D) Thickness of the left ventricular posterior wall in diastole (LVPWd). Values are expressed as percentage of TL. (E) Internal diameter of the left ventricle in diastole (LVIDd) as percentage of TL. (F) E-wave deceleration rate (EWDR) of the mitral flow. (G) The isovolumic relaxation time (IVRT) of the left ventricle. (H) Early tissue Doppler velocity (E′). (I) Representative PV loops. (J) dP/dt max. (K) End-systolic pressure-volume relationship (ESPVR). (L) End-diastolic pressure-volume relationship (EDPVR). (M) Tau Glantz.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts